XML 231 R38.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Investments (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Investments [Abstract] |
Schedule of Long-Term Investments | These below equity investments are included in investments on the consolidated balance sheets as of December 31, 2021 and 2020 (in thousands):
|  | 2021 |  | 2020
ShiraTronics, Inc. |  | $ | 3,331 |  |  | $ | 2,045 |
Noctrix Health, Inc. |  | 3,159 |  |  | 1,359 |
ALung Technologies, Inc. (1) |  | 3,000 |  |  | 3,000 |
Ceribell, Inc. |  | 3,000 |  |  | 3,000 |
MD Start II (2) |  | 1,135 |  |  | 1,227 |
Rainbow Medical Ltd. |  | 1,111 |  |  | 1,201 |
Highlife S.A.S. |  | 1,075 |  |  | 1,163 |
Respicardia Inc. (3) |  | — |  |  | 17,706 |
|  | 15,811 |  |  | 30,701 |
Equity method investment (4) |  | 787 |  |  | 393 |
|  | $ | 16,598 |  |  | $ | 31,094 |
(1)ALung Technologies, Inc. (“ALung”) is a privately held medical device company focused on creating advanced medical devices for treating respiratory failure. We have a loan outstanding to ALung with a carrying amount of $2.5 million and $2.5 million as of December 31, 2021 and 2020, respectively, which is included in prepaid expenses and other current assets on the consolidated balance sheet. (2)During the second quarter of 2021 the Company received a cash dividend from its investment in MD Start II of $3.1 million, which is included in foreign exchange and other gains/(losses) on the consolidated statements of income (loss) for the year ended December 31, 2021. (3)In April 2021, Zoll Medical Corporation acquired Respicardia Inc. As a result of the acquisition we received proceeds of $23.1 million for our investment and loan receivable with carrying values of $17.7 million and $0.8 million as of December 31, 2020, respectively. The Company recorded a gain of $4.6 million during the first quarter of 2021 to adjust the investment and loans receivable to fair value, which is included in foreign exchange and other gains/(losses) on the consolidated statements of income (loss) for the year ended December 31, 2021. (4)We are required to fund follow-on investments up to a total of approximately €5.0 million (approximately $5.7 million as of December 31, 2021) based on cash calls.

X
- Definition Tabular disclosure of data and information required in the supplementary schedule applicable to management investment companies listing holdings of unaffiliated investments. + References No definition available. + Details
Name: | us-gaap_InvestmentHoldingsScheduleOfInvestmentsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration